Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterized by cytopenia(s), dysplasia in one or more major myeloid cell lines and progression to acute leukemia. Morphological analysis of peripheral blood (PB) and bone marrow (BM) remains the cornerstone of the diagnosis. Preliminary studies identified Flow Cytometry (FC) markers on red cells, platelets and circulating leukocytes that are expressed differently in MDS and in controls. However, these markers have been evaluated separately. The investigators propose to test in a large cohort of patients these markers, and to combine the most relevant ones in order to define a PB FC-based diagnosis score that would discriminate between MDS and non-clonal hematopoiesis and would avoid useless bone marrow samples in elderly

NCT Number	NCT03621241
Lead Sponsor	Centre Hospitalier Universitaire, Amiens
Conditions	Myelodysplastic Syndromes
Enrollment	300 participants
Start Date	2018-06-15
Primary Completion	2024-08 (estimated)
Study Completion	2024-12 (estimated)
Updated on ClinicalTrials.gov	2024-07-10